Equillium, Inc. (EQ) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Equillium, Inc. is a biotechnology innovator developing novel therapies for severe autoimmune and inflammatory disorders. The company's primary focus is advancing EQ504, a novel aryl hydrocarbon receptor modulator. As of the reporting date, the company had paused all research and development activities pending capital raises. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $0 | $13.9 million | $0 | $24.5 million |
| Net Loss | $(5.7 million) | $0.5 million (Income) | $(14.4 million) | $(2.3 million) |
| Operating Expenses | $6.2 million | $14.0 million | $15.1 million | $27.4 million |
| Cash & Equivalents (End of Period) | $11.5 million | $11.1 million | $11.5 million | $11.1 million |
| Accumulated Deficit | $(208.2 million) | $(188.0 million) | $(208.2 million) | $(188.0 million) |
| Stockholders' Equity | $5.1 million | $22.4 million | $5.1 million | $22.4 million |
Liquidity: Cash and cash equivalents decreased from $18.1 million at year-end 2024 to $11.5 million at June 30, 2025. The company had no short-term investments as of June 30, 2025, compared to $4.5 million at year-end 2024.
Material Changes vs. Prior Period
- Revenue Cessation: Revenue dropped to zero in Q2 2025 compared to $13.9 million in Q2 2024. This is due to the expiration of the Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd. on October 30, 2024, which previously provided development funding and upfront payment amortization.
- Expense Reduction: Total operating expenses decreased significantly to $6.2 million in Q2 2025 from $14.0 million in Q2 2024. This reduction is attributed to the wind-down of clinical studies, CMC activities, and decreased employee compensation.
- Profitability Shift: The company swung from a net income of $0.5 million in Q2 2024 to a net loss of $5.7 million in Q2 2025, driven by the loss of revenue and continued operational costs.
- Equity Dilution: Stockholders' equity declined from $22.4 million in Q2 2024 to $5.1 million in Q2 2025, reflecting the accumulated deficit and net losses.
Guidance, Outlook, and Risks
- Capital Raise (Subsequent Event): On August 12, 2025, the company completed an initial closing of a private placement, raising approximately $30.0 million in gross proceeds. This alleviated substantial doubt regarding the company's ability to continue as a going concern. Management believes this, combined with existing cash, will fund operations through 2027.
- Development Pause: R&D activities were paused in Q2 2025 pending capital. The company intends to resume development of EQ504, targeting a Phase 1 proof-of-mechanism study by mid-2026.
- Itolizumab (EQ001) Status: Following FDA feedback in April 2025 regarding the Phase 3 EQUATOR study (which did not meet primary Day 29 outcomes but showed longer-term benefits), the company accelerated study closure. There are no current plans for further clinical development of itolizumab, and the company may consider terminating its license with Biocon.
- Nasdaq Compliance: The company received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement. It was granted an extension until December 8, 2025, to regain compliance or face delisting.
- Cryptocurrency Strategy: The company announced a treasury strategy to include digital currencies but has not yet initiated investments, prioritizing EQ504 development instead.
Investor Verification Checklist
- Runway Confirmation: Verify the net proceeds from the August 2025 private placement and confirm the projected cash runway through 2027.
- Nasdaq Status: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement by the December 8, 2025 deadline to avoid delisting.
- EQ504 Timeline: Track the initiation of the Phase 1 proof-of-mechanism study for EQ504, currently targeted for mid-2026.
- Itolizumab License: Watch for announcements regarding the potential termination of the Biocon license or alternative monetization strategies for itolizumab.
- Dilution Impact: Assess the impact of the recent private placement (21.8 million shares + 30.8 million pre-funded warrants) and potential milestone closings on existing shareholder ownership.